Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases

详细信息    查看全文

• 作者：Masayuki Kanamori (1)
  Toshihiro Kumabe (1)
  Ichiyo Shibahara (1)
  Ryuta Saito (1)
  Yoji Yamashita (1)
  Yukihiko Sonoda (1)
  Hiroyoshi Suzuki (2)
  Mika Watanabe (3)
  Teiji Tominaga (1)
  
• 关键词：Recurrent oligodendroglial tumor ; IDH1/2 gene ; p53 ; 1p/19q co ; deletion ; Ki ; 67 labeling index
• 刊名：Brain Tumor Pathology
• 出版年：2013
• 出版时间：July 2013
• 年：2013
• 卷：30
• 期：3
• 页码：151-159
• 全文大小：4013KB
• 参考文献：1. Committee of Brain Tumor Registry of Japan (2009) Report of Brain Tumor Registry of Japan (1984鈥?000), 12th edition. Neurol Med Chir (Tokyo) 49 Suppl:i鈥搗ii, 1鈥?01
  2. Jaeckle KA, Decker PA, Ballman KV et al (2011) Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol 104:253鈥?59 CrossRef
  3. Fallon KB, Palmer CA, Roth KA et al (2004) Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314鈥?22
  4. Campbell BA, Horsman DE, Maguire J et al (2008) Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? J Neurooncol 89:37鈥?5 CrossRef
  5. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597鈥?02 CrossRef
  6. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807鈥?812 CrossRef
  7. Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996鈥?998 CrossRef
  8. Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719鈥?29 CrossRef
  9. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol 14:109鈥?16 CrossRef
  10. van den Bent MJ, Dubbink HJ, Marie Y et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16:1597鈥?604 CrossRef
  11. Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341鈥?47 CrossRef
  12. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
  13. Kanamori M, Kumabe T, Sonoda Y, Nishino Y, Watanabe M, Tominaga T (2009) Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol 93:219鈥?28 CrossRef
  14. van den Bent MJ, Afra D, de Witte O et al (2005) EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985鈥?90 CrossRef
  15. Kraus JA, Lamszus K, Glesmann N et al (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 101:311鈥?20
  16. He J, Mokhtari K, Sanson M et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 60:863鈥?71
  17. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419鈥?426 CrossRef
  18. Marucci G (2011) The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. J Neurooncol 104:621鈥?22 CrossRef
  19. Qu M, Olofsson T, Sigurdardottir S et al (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113:129鈥?36 CrossRef
  20. Perry A, Brat DJ (2010) Practical surgical neuropathology. Elsevier, Philadelphia, p 421
  
• 作者单位：Masayuki Kanamori (1)
  Toshihiro Kumabe (1)
  Ichiyo Shibahara (1)
  Ryuta Saito (1)
  Yoji Yamashita (1)
  Yukihiko Sonoda (1)
  Hiroyoshi Suzuki (2)
  Mika Watanabe (3)
  Teiji Tominaga (1)
  
  1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
  2. Department of Pathology and Laboratory Medicine, Sendai Medical Center, Sendai, Japan
  3. Department of Pathology, Tohoku University Hospital, Sendai, Japan
  
• ISSN：1861-387X

文摘

Changes in histological and genetic characteristics were investigated in 18 paired primary and recurrent oligodendroglial tumors, using sequencing analysis for isocitrate dehydrogenase (IDH) 1 and 2 gene mutation, Ki-67 and p53 immunohistochemistry, and fluorescent in situ hybridization for loss of heterozygosity of chromosomes 1p and 19q (1p/19q co-deletion). Malignant transformation occurred in 5 of 8 cases with World Health Organization (WHO) grade II tumors, but in 0 of 10 cases with WHO grade III tumors progressing to glioblastoma. Thirteen of the 18 cases carried IDH1 gene mutation. Tumors with IDH1 mutation tended to survive for longer, even after recurrence, but newly developed microvascular proliferation, tumor necrosis, and elevated Ki-67 labeling index were common. Eleven of the 13 IDH1-mutation tumors had either 1p/19q co-deletion or nuclear expression of p53, but all 5 IDH1/2 wild-type tumors had neither. All cases had the same profile for 1p/19q status at recurrence, but nuclear expression of p53 changed from negative to positive in 2 of 6 cases with IDH1 mutation and 1p/19q co-deletion. WHO grade II oligodendroglial tumors show a high rate of malignant transformation, possibly involving p53 in tumors with IDH1 mutation and 1p/19q co-deletion. Tumors with IDH1 mutation had a more aggressive histological phenotype despite their better prognosis.